Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, PE Corporation, Nanogen and Becton

Premium

A new US Patent has issued for Illumina scientific founder David Walt’s microsphere-based analyte detection platform. The patent, Number 6,327,410, is entitled “Target analyte sensors utilizing microspheres,” and is assigned to Tufts University, where Walt has his research lab. The patent covers a method in which microspheres that carry bioactive agents are dispersed onto a substrate then target analytes are detected for these agents using an optical signature encoding scheme. The patent covers a wide variety of substrates, both two- and three-dimensional. But the preferred embodiment is that which San Diego-based Illumina has adopted, a “modified fiber optic bundle or array.” Illumina’s BeadArray technology consists of DNA strands attached to microspheres, which then fit into the hemispherical craters at the ends of these fiber optic bundles. Up to 2,000 different genes, with 50,000 genes per bead, can fit into the end of a single bundle. The company then arrays these bundles into hairbrush like matrices on a cassette that can fit into the wells of a 96-well plate. Given that each bead includes hundreds of thousands of molecules, the technology can provide a sensitive platform for analyte detection.

PE Corporation (now Applera), received two US patents covering nucleic acid molecules that encode human lipase proteins and human enzymes, as well as the proteins and enzymes themselves. The inventions also provide for methods of identifying these particular molecules using microarrays. The lipase proteins, described in Patent Number 6,326,182, include those related to the hormone-sensitive lipase (arylacetamide deacetylase) subfamily. The enzymes, covered in Patent Number 6,326,180, include those related to the steroid oxidoreductase subfamily.

 

In the latest milestone of the joint technology venture they began in 1997, Nanogen and Becton, Dickinson have received a patent covering a method of amplifying nucleic acids using electronically induced hybridization of target nucleic acids to the primer. This patent, US Patent Number 6,326,173, “Electronically mediated nucleic acid amplification in NASBA,” details a method known as nucleic acid sequence-based amplification. The method, in addition to using electronics, also uses strand displacement amplification, which requires less temperature control than PCR. It is designed to make amplification much faster and more efficient.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.